Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1

Kevin M. Lin-Hurtubise, Christopher G. Yheulon, Ronald A. Gagliano, Henry T. Lynch

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background The lynch syndrome (LS) tumor spectrum involves colorectal cancer (CRC), endometrial cancer (EC), and less frequently various extracolonic non-endometrial cancers (non-EC). The organ-specific survival rates of these patients are well defined, however, the collective survival of all-cancers combined (CRC + EC + non-EC) are unclear. Methods Fifty-two MSH2 patients and 68 MLH1 patients were followed for a median of 6.3 years after diagnosis of first cancer, regardless of type. The proportions of CRC only, EC, non-EC, and multiple primary cancers were compared between the two genotypes. Kaplan-Meier curves were developed for survival comparisons. Results MSH2 patients present less frequently with only CRC (37% MSH2, 62% MLH1, P = 0.0096), manifest more multiple primary cancers (38% MSH2, 18% MLH1, P = 0.013), develop more extracolonic cancers (62% MSH2, 38% MLH1, P = 0.003), non-EC only cancers (46% MSH2, 24% MLH1, P = 0.028) and carry a greater risk for urinary tract cancer (UTC) (13.4% MSH2, 1.5% MLH1, P = 0.024). There was no difference in 10-year survival between the two groups (P = 0.4). Conclusion The additional propensity for UTC in MSH2 carriers argues in favor of UTC screening in MSH2 individuals. Other types of cancer screening should be tailored to the expression history of the specific LS mutation. J. Surg. Oncol. 2013; 108:433-437.

Original languageEnglish
Pages (from-to)433-437
Number of pages5
JournalJournal of Surgical Oncology
Volume108
Issue number7
DOIs
StatePublished - Dec 2013

Fingerprint

Germ-Line Mutation
Neoplasms
Urologic Neoplasms
Colorectal Neoplasms
Endometrial Neoplasms
Hereditary Nonpolyposis Colorectal Neoplasms
Early Detection of Cancer
Survival
Tissue Survival
Survival Rate
Genotype

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1. / Lin-Hurtubise, Kevin M.; Yheulon, Christopher G.; Gagliano, Ronald A.; Lynch, Henry T.

In: Journal of Surgical Oncology, Vol. 108, No. 7, 12.2013, p. 433-437.

Research output: Contribution to journalArticle

Lin-Hurtubise, Kevin M. ; Yheulon, Christopher G. ; Gagliano, Ronald A. ; Lynch, Henry T. / Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1. In: Journal of Surgical Oncology. 2013 ; Vol. 108, No. 7. pp. 433-437.
@article{a691a8e3286c4752850c2a4eb5d30cfe,
title = "Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1",
abstract = "Background The lynch syndrome (LS) tumor spectrum involves colorectal cancer (CRC), endometrial cancer (EC), and less frequently various extracolonic non-endometrial cancers (non-EC). The organ-specific survival rates of these patients are well defined, however, the collective survival of all-cancers combined (CRC + EC + non-EC) are unclear. Methods Fifty-two MSH2 patients and 68 MLH1 patients were followed for a median of 6.3 years after diagnosis of first cancer, regardless of type. The proportions of CRC only, EC, non-EC, and multiple primary cancers were compared between the two genotypes. Kaplan-Meier curves were developed for survival comparisons. Results MSH2 patients present less frequently with only CRC (37{\%} MSH2, 62{\%} MLH1, P = 0.0096), manifest more multiple primary cancers (38{\%} MSH2, 18{\%} MLH1, P = 0.013), develop more extracolonic cancers (62{\%} MSH2, 38{\%} MLH1, P = 0.003), non-EC only cancers (46{\%} MSH2, 24{\%} MLH1, P = 0.028) and carry a greater risk for urinary tract cancer (UTC) (13.4{\%} MSH2, 1.5{\%} MLH1, P = 0.024). There was no difference in 10-year survival between the two groups (P = 0.4). Conclusion The additional propensity for UTC in MSH2 carriers argues in favor of UTC screening in MSH2 individuals. Other types of cancer screening should be tailored to the expression history of the specific LS mutation. J. Surg. Oncol. 2013; 108:433-437.",
author = "Lin-Hurtubise, {Kevin M.} and Yheulon, {Christopher G.} and Gagliano, {Ronald A.} and Lynch, {Henry T.}",
year = "2013",
month = "12",
doi = "10.1002/jso.23413",
language = "English",
volume = "108",
pages = "433--437",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1

AU - Lin-Hurtubise, Kevin M.

AU - Yheulon, Christopher G.

AU - Gagliano, Ronald A.

AU - Lynch, Henry T.

PY - 2013/12

Y1 - 2013/12

N2 - Background The lynch syndrome (LS) tumor spectrum involves colorectal cancer (CRC), endometrial cancer (EC), and less frequently various extracolonic non-endometrial cancers (non-EC). The organ-specific survival rates of these patients are well defined, however, the collective survival of all-cancers combined (CRC + EC + non-EC) are unclear. Methods Fifty-two MSH2 patients and 68 MLH1 patients were followed for a median of 6.3 years after diagnosis of first cancer, regardless of type. The proportions of CRC only, EC, non-EC, and multiple primary cancers were compared between the two genotypes. Kaplan-Meier curves were developed for survival comparisons. Results MSH2 patients present less frequently with only CRC (37% MSH2, 62% MLH1, P = 0.0096), manifest more multiple primary cancers (38% MSH2, 18% MLH1, P = 0.013), develop more extracolonic cancers (62% MSH2, 38% MLH1, P = 0.003), non-EC only cancers (46% MSH2, 24% MLH1, P = 0.028) and carry a greater risk for urinary tract cancer (UTC) (13.4% MSH2, 1.5% MLH1, P = 0.024). There was no difference in 10-year survival between the two groups (P = 0.4). Conclusion The additional propensity for UTC in MSH2 carriers argues in favor of UTC screening in MSH2 individuals. Other types of cancer screening should be tailored to the expression history of the specific LS mutation. J. Surg. Oncol. 2013; 108:433-437.

AB - Background The lynch syndrome (LS) tumor spectrum involves colorectal cancer (CRC), endometrial cancer (EC), and less frequently various extracolonic non-endometrial cancers (non-EC). The organ-specific survival rates of these patients are well defined, however, the collective survival of all-cancers combined (CRC + EC + non-EC) are unclear. Methods Fifty-two MSH2 patients and 68 MLH1 patients were followed for a median of 6.3 years after diagnosis of first cancer, regardless of type. The proportions of CRC only, EC, non-EC, and multiple primary cancers were compared between the two genotypes. Kaplan-Meier curves were developed for survival comparisons. Results MSH2 patients present less frequently with only CRC (37% MSH2, 62% MLH1, P = 0.0096), manifest more multiple primary cancers (38% MSH2, 18% MLH1, P = 0.013), develop more extracolonic cancers (62% MSH2, 38% MLH1, P = 0.003), non-EC only cancers (46% MSH2, 24% MLH1, P = 0.028) and carry a greater risk for urinary tract cancer (UTC) (13.4% MSH2, 1.5% MLH1, P = 0.024). There was no difference in 10-year survival between the two groups (P = 0.4). Conclusion The additional propensity for UTC in MSH2 carriers argues in favor of UTC screening in MSH2 individuals. Other types of cancer screening should be tailored to the expression history of the specific LS mutation. J. Surg. Oncol. 2013; 108:433-437.

UR - http://www.scopus.com/inward/record.url?scp=84887171683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887171683&partnerID=8YFLogxK

U2 - 10.1002/jso.23413

DO - 10.1002/jso.23413

M3 - Article

VL - 108

SP - 433

EP - 437

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -